<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052624</url>
  </required_header>
  <id_info>
    <org_study_id>MUSC-10550</org_study_id>
    <secondary_id>KSB-311P/CI/001</secondary_id>
    <secondary_id>CDR0000258574</secondary_id>
    <nct_id>NCT00052624</nct_id>
  </id_info>
  <brief_title>Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma</brief_title>
  <official_title>A Phase I Multicenter Trial Of Intratumoral/Interstitial Therapy With HN66000, NC66000 (TransMID) In Patients Between 5 and 18 Years Of Age With Progressive Or Recurrent Glioblastoma Multiforme Or Anaplastic Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xenova Biomedix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells.&#xD;
      Immunotoxin therapy may be an effective treatment for glioblastoma multiforme and anaplastic&#xD;
      astrocytoma.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy in treating children&#xD;
      who have progressive or recurrent glioblastoma multiforme or anaplastic astrocytoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intratumoral transferrin-CRM107 in pediatric&#xD;
           patients with progressive or recurrent glioblastoma multiforme or anaplastic&#xD;
           astrocytoma.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug in these patients.&#xD;
&#xD;
        -  Compare the efficacy of this drug in patients with different histological types of&#xD;
           tumor, degrees of transferrin receptor expression, and serum antidiphtheria antibody&#xD;
           titer levels.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label, multicenter study. Patients are assigned to 1&#xD;
      of 2 treatment groups by age (5-9 vs 10-18).&#xD;
&#xD;
      All patients undergo stereotactic radiosurgery for tumor biopsy and placement of 2&#xD;
      intratumoral silastic infusion catheters pre-loaded with transferrin-CRM107 (Tf-CRM107).&#xD;
&#xD;
        -  Group 1 (ages 5-9): Patients receive intratumoral Tf-CRM107 over 3-7 days via catheter.&#xD;
           Treatment repeats after 6-10 weeks in the absence of unacceptable toxicity. Three&#xD;
           cohorts of 3-6 patients receive escalating doses of Tf-CRM107 until the maximum&#xD;
           tolerated dose (MTD) is determined.&#xD;
&#xD;
        -  Group 2 (ages 10-18): Patients receive intratumoral Tf-CRM107 as in group 1. Two cohorts&#xD;
           of 3-6 patients receive escalating doses of Tf-CRM107 until the MTD is determined.&#xD;
&#xD;
      The MTD in both groups is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for 6 months and then every 3 months for 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>transferrin-CRM107</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme or anaplastic astrocytoma with the&#xD;
             following tumor characteristics:&#xD;
&#xD;
               -  Unifocal&#xD;
&#xD;
               -  Unilateral and supratentorial&#xD;
&#xD;
               -  Diameter no greater than 3.5 cm by contrast-enhanced MRI&#xD;
&#xD;
          -  No more than 1 satellite tumor&#xD;
&#xD;
          -  Recurrent or progressive disease&#xD;
&#xD;
               -  Progressive disease defined as at least 25% increase in tumor volume by serial&#xD;
                  MRI or CT scans and/or at least 15% increase in the largest cross-sectional area&#xD;
                  of tumor as defined by the area of contrast agent enhancement&#xD;
&#xD;
          -  Must have received prior conventional treatment comprising both of the following:&#xD;
&#xD;
               -  Surgery (biopsy or debulking)&#xD;
&#xD;
               -  Radiation therapy&#xD;
&#xD;
          -  No evidence of mass effect on CT scan or MRI with more than a 5 mm midline shift&#xD;
             and/or nausea, vomiting, reduced level of consciousness, or clinically significant&#xD;
             papilledema&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  5 to 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100% OR&#xD;
&#xD;
          -  Lansky Play 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  PT or aPTT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 2 months&#xD;
             after study&#xD;
&#xD;
          -  No acute viral, bacterial, or fungal infection requiring therapy&#xD;
&#xD;
               -  Topical treatment for oral candidiasis allowed&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude anesthesia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior transferrin-CRM107&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 1 month since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  More than 3 months since prior biodegradable polymer wafers&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Must be on stable dose of steroids for 7 days prior to infusion&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior radiotherapy&#xD;
&#xD;
          -  More than 3 months since prior stereotactic radiosurgery&#xD;
&#xD;
          -  More than 6 weeks since prior craniospinal irradiation&#xD;
&#xD;
          -  No prior brachytherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 1 month since prior surgery including tumor surgery or debulking&#xD;
&#xD;
          -  No other concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent anti-cancer drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Rossi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Xenova Biomedix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

